FINWIRES · TerminalLIVE
FINWIRES

KSH Forecasts Fiscal 2026 Net Profit Turnaround on Construction Recovery

By

KSH (SGX:ER0) is expecting to book a net profit for both the second half of the fiscal year and the full financial year ended March 31, compared with a net loss a year earlier, according to a Thursday filing with the Singapore Exchange.

Shares of the construction engineering company were down 1% in Friday trading.

The company has attributed this to a steady rebound in its construction business contributions.

KSH will release its financial results on or around May 28, the filing said.

Related Articles

Asia

Siyaram Recycling Clinches Over INR26 Million Brass Scrap Supply Order; Shares Up 5%

Siyaram Recycling Industries (BOM:544047) has secured an order worth 26.4 million Indian rupees from Saanvi Metal Craft, according to a BSE filing on Friday.The domestic order is for the supply of brass scrap honey within seven days.The company's shares were up nearly 5% in recent trade.

$BOM:544047
Asia

Market Chatter: AMD Ramps Up Taiwan Partnerships to Combat CPU Supply Shortages

US-based semiconductor designer AMD is expanding production efforts with Taiwanese partners as unexpectedly strong demand tightens global CPU supply, Reuters reported Friday, citing CEO Lisa Su.Su said the company is coordinating closely with key customers across China and other markets, with a focus on ensuring capacity can support a sharp rise in central processing unit output. She added that Taiwan remains central to global semiconductor manufacturing through firms such as Taiwan Semiconductor Manufacturing (TPE:2330), according to the report.She described the CPU market as increasingly constrained, driven by AI inference and emerging agentic systems, and said AMD expects supply to rise quarter by quarter, with further expansion planned into 2027 and beyond, the news agency said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^TWII$TPE:2330
Asia

Salubris Pharma's Clinical Trial Application for Lipid-Lowering Drug Accepted in China

Shenzhen Salubris Pharmaceuticals (SHE:002294) said China's drug regulator accepted its clinical trial application for SAL0195.The drug targets lipid-related diseases, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company were down 2% in recent trade.

$SHE:002294